Skip to content
Search

Latest Stories

AI spots heart conditions before symptoms appear

The AI tool, developed by researchers at the University of Leeds and Leeds Teaching Hospitals NHS Trust, is part of the Find-AF trial

AI spots heart conditions before symptoms appear

The trial sees the AI system scanning GP records at multiple surgeries in West Yorkshire (Photo for representation: iStock)

A NEW artificial intelligence (AI) tool is revolutionising the early detection of atrial fibrillation (AF), a common heart condition linked to a heightened risk of stroke.

This innovative approach is currently undergoing trials in West Yorkshire, where it analyses patient records to spot early warning signs of AF, even before symptoms develop, reported the Telegraph.


AF, which causes an irregular and often rapid heart rate, affects approximately 1.6 million people in the UK. However, experts from the British Heart Foundation (BHF) estimate that thousands more cases remain undiagnosed. While some patients with AF experience symptoms such as palpitations, dizziness, or fatigue, many remain asymptomatic and unaware of their condition. Early diagnosis is crucial, as timely treatment can significantly reduce the risk of stroke.

The AI tool, developed by researchers at the University of Leeds and Leeds Teaching Hospitals NHS Trust, is part of the Find-AF trial funded by the BHF and Leeds Hospitals Charity.

By analysing anonymised health records from over 2.1 million individuals, the algorithm has been trained to recognise patterns and risk factors indicative of potential AF cases. It was further validated using data from an additional 10 million medical records.

The trial sees the AI system scanning GP records at multiple surgeries in West Yorkshire. Patients identified as high-risk are invited for further testing. They are given handheld electrocardiography (ECG) devices to monitor their heart rhythm twice daily over four weeks or whenever they experience palpitations. If the ECG detects AF, the results are shared with their GP to discuss potential treatments.

John Pengelly, a former Army captain, credits the AI tool for identifying his elevated risk of AF. “I’m really grateful,” he said. “Now, I just take a couple of pills a day to lower my stroke risk.”

Prof Chris Gale, a cardiovascular medicine specialist at the University of Leeds, explained the importance of early detection: “All too often, the first sign of undiagnosed AF is a stroke, which can have devastating consequences for patients and their families. Identifying AF earlier can prevent such outcomes and reduce the financial burden on healthcare services.”

The AI system calculates risk using a combination of factors, including age, sex, ethnicity, and pre-existing conditions like high blood pressure or diabetes. This targeted approach aims to make the diagnosis process more efficient and accessible. The trial’s success could pave the way for a nationwide rollout, potentially preventing thousands of strokes annually. AF is believed to contribute to around 20,000 strokes in the UK each year.

Dr Sonya Babu-Narayan, associate medical director at the BHF, highlighted the potential impact of this technology: “By leveraging routinely collected healthcare data and predictive algorithms, this research offers an exciting opportunity to identify more individuals at risk of AF and reduce their stroke risk.”

Health secretary Wes Streeting recently praised the transformative potential of AI in healthcare, noting its ability to “predict and prevent illness”.

More For You

weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less
Weight Loss Drug

Health officials expect the rollout to benefit around 220,000 adults over the next 3 years

iStock

NHS GPs to prescribe Mounjaro in nationwide obesity treatment plan

Key points

  • NHS GPs in England can now prescribe Mounjaro (tirzepatide) for weight loss
  • The programme aims to support 220,000 people over three years
  • Eligible patients must have a BMI over 40 and at least four obesity-related health issues
  • GP leaders raise concerns over increased workload
  • Pharmacists urge a broader weight management approach

NHS expands obesity treatment with Mounjaro

The NHS in England is set to begin prescribing Mounjaro, a weight loss injection, through GP surgeries starting Monday. The move marks the first time family doctors will be authorised to directly prescribe the anti-obesity drug tirzepatide as part of a wider national health initiative.

Health officials expect the rollout to benefit around 220,000 adults over the next three years. The drug will be made available to those with a body mass index (BMI) above 40 who also suffer from at least four other obesity-related conditions, such as type 2 diabetes, high blood pressure, or sleep apnoea.

Keep ReadingShow less
UK heatwave deaths

Around 85% of the projected deaths are likely to involve people over the age of 65

iStock

Scientists warn current UK heatwave may cause nearly 600 early deaths

Almost 600 premature deaths are expected to occur during the ongoing heatwave affecting England and Wales, according to a new rapid analysis by leading scientists. The majority of fatalities are projected among older adults, with London and the West Midlands likely to be the worst-affected areas.

Climate change driving deadly temperatures

Researchers say the extreme temperatures, which have reached 32°C in parts of south-east England, would have been nearly impossible without the influence of human-caused climate change. Pollution from burning fossil fuels has raised the likelihood of such heatwaves by around 100 times, experts say.

Keep ReadingShow less
Amycretin

'The Lancet' and presentations at the American Diabetes Association’s 2025

iStock

New weight-loss pill Amycretin shows greater impact than jabs, study finds

A new weight-loss drug, amycretin, has delivered the most significant results yet for appetite-suppressing GLP-1 medications, according to two newly published studies in The Lancet and presentations at the American Diabetes Association’s 2025 Scientific Sessions in Chicago.

Record weight loss from Amycretin injections

Researchers found that participants receiving high-dose weekly injections of amycretin lost 24.3 per cent of their body weight over 36 weeks. This outcome surpasses the results seen in longer trials involving other GLP-1 drugs such as tirzepatide (sold as Mounjaro), which previously led the field with an average weight loss of 20 per cent over 72 weeks.

Keep ReadingShow less
Hulk Hogan

Hogan’s current hospital stay follows a neck fusion surgery he underwent in May 2025

Getty Images

Hulk Hogan hospitalised for back and neck issues, rep confirms he is not on deathbed

WWE Hall of Famer Hulk Hogan has been hospitalised for ongoing neck and back issues, but representatives have confirmed he is not in critical condition, dismissing online speculation suggesting otherwise.

The 71-year-old wrestling icon, whose real name is Terry Bollea, was reported by TMZ Sports to be undergoing treatment related to injuries sustained during his decades-long in-ring career. His representative said Hogan is already mobile again and “not on his deathbed”, following false claims made on air by Florida radio personality Bubba the Love Sponge.

Keep ReadingShow less